NASDAQ · Biotechnology

Aadi Bioscience, Inc. (AADI) Stock

$2.05 -2.38% NASDAQ: AADI Healthcare

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway.

Valuation

MetricValue
Price$2.05
Market Cap$94.89M
P/E Ratio-1.49
P/B Ratio1.22
P/S Ratio13.56
EPS (TTM)$-0.03
52-Week High$3.81
52-Week Low$1.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-79.63%
ROA-91.02%
ROCE-105.62%
Gross Margin-1642.86%
Operating Margin-1628.57%
Net Margin-300.00%
Debt/Equity0.00
Current Ratio11.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$15.0M$24.0M$26.0M$7.0M
Operating Profit$-111.0M$-59.0M$-72.0M$-67.0M$-114.0M
Net Profit$-110.0M$-61.0M$-66.0M$-64.0M$-21.0M
EPS$-12.41$-2.69$-2.44$-2.36$-0.03
Op Margin-9930.1%-387.5%-295.4%-259.6%-1601.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$158.0M$184.0M$132.0M$70.0M$151.0M
Total Liabilities$22.0M$26.0M$27.0M$18.0M$15.0M
Cash$149.0M$39.0M$63.0M$29.0M$38.0M
Borrowings$1.0M$2.0M$1.0M$1.0M$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-50.0M$-60.0M$-60.0M$-97.0M
Investing Cash Flow$25.0M$-133.0M$79.0M$24.0M$11.0M
Financing Cash Flow$-9.0M$0$0$0$94.0M
Net Cash Flow$145.0M$-110.0M$24.0M$-34.0M$9.0M
Free Cash Flow$-22.0M$-50.0M$-64.0M$-61.0M$-98.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.51
FCF Yield-10.32%
Quick Ratio11.36
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASXCAsensus Surgical, Inc. $0.35 +0.64% -1.12 $94.92M 0.00%
BLIBerkeley Lights, Inc. $1.20 -5.88% -0.85 $86.61M 0.00%
HLVXHilleVax, Inc. $2.09 -0.48% -9.09 $104.76M 0.00%
IGMSIGM Biosciences, Inc. $1.27 +0.00% 1.75 $77.50M 0.00%
IMDXInsight Molecular Diagnostics Inc. $4.70 -0.84% -3.13 $151.76M 0.00%

About Aadi Bioscience, Inc.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.

Aadi Bioscience, Inc. is headquartered in US.

Aadi Bioscience, Inc. (AADI) stock trades at $2.05 with a market capitalization of $94.89M. The stock is valued at a price-to-earnings (P/E) ratio of -1.49, price-to-book of 1.22, price-to-sales of 13.56. Over the past 52 weeks the stock has ranged between $1.21 and $3.81, and currently trades 46.2% below its 52-week high.

On profitability, Aadi Bioscience, Inc. generates a return on equity (ROE) of -79.63%, return on capital employed of -105.62%, an operating margin of -1628.57%, a net profit margin of -300.00%.

Official website: aadibio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides